BAUMGARTNER ROBERT V 4
4 · BIO-TECHNE Corp · Filed Aug 25, 2021
Insider Transaction Report
Form 4
BIO-TECHNE CorpTECH
BAUMGARTNER ROBERT V
Director
Transactions
- Exercise/Conversion
Common Stock
2021-08-23$87.39/sh+4,000$349,560→ 13,612 total - Sale
Common Stock
2021-08-23$481.77/sh−299$144,050→ 13,313 total - Sale
Common Stock
2021-08-23$485.03/sh−600$291,015→ 12,112 total - Sale
Common Stock
2021-08-23$487.10/sh−800$389,682→ 9,712 total - Exercise/Conversion
Stock Options (right to buy)
2021-08-23−4,000→ 0 totalExercise: $87.39From: 2013-10-31Exp: 2023-10-30→ Common Stock (4,000 underlying) - Sale
Common Stock
2021-08-23$483.60/sh−601$290,643→ 12,712 total - Sale
Common Stock
2021-08-23$486.25/sh−1,600$778,004→ 10,512 total - Sale
Common Stock
2021-08-23$487.88/sh−100$48,788→ 9,612 total
Holdings
- 4,000
Stock Options (right to buy)
Exercise: $91.78From: 2014-10-30Exp: 2024-10-30→ Common Stock (4,000 underlying) - 1,898
Stock Options (right to buy)
Exercise: $179.84From: 2019-10-24Exp: 2028-10-25→ Common Stock (1,898 underlying) - 3,125
Stock Options (right to buy)
Exercise: $125.05From: 2018-10-25Exp: 2027-10-26→ Common Stock (3,125 underlying) - 2,011
Stock Options (right to buy)
Exercise: $201.64From: 2020-10-24Exp: 2029-10-24→ Common Stock (2,011 underlying) - 4,260
Stock Options (right to buy)
Exercise: $87.34From: 2016-10-29Exp: 2025-10-28→ Common Stock (4,260 underlying) - 3,985
Stock Options (right to buy)
Exercise: $101.19From: 2017-10-26Exp: 2026-10-26→ Common Stock (3,985 underlying) - 1,507
Stock Options (right to buy)
Exercise: $255.69Exp: 2030-10-29→ Common Stock (1,507 underlying)
Footnotes (7)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $481.41 to $482.40, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $483.01 to $483.86, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $484.52 to $485.51, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $485.59 to $486.51, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $486.84 to $487.52, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $487.87 to $487.89, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]The option vests on the earlier of the one year anniversary of the grant date (10/29/20) or the date of Bio-Techne's 2021 annual meeting of shareholders.